Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 234Carcinoma, Non-Small-Cell Lung 132Breast Neoplasms 121Glioblastoma 88Ovarian Neoplasms 86Carcinoma, Hepatocellular 69Rectal Neoplasms 64Brain Neoplasms 58Lung Neoplasms 55Neoplasm Metastasis 54Neoplasms 52Colonic Neoplasms 50Fallopian Tube Neoplasms 43Glioma 40Carcinoma, Renal Cell 35Gliosarcoma 34Melanoma 26Adenocarcinoma of Lung 26Pancreatic Neoplasms 23Liver Neoplasms 23Uterine Cervical Neoplasms 21Stomach Neoplasms 21Recurrence 21Triple Negative Breast Neoplasms 18Kidney Neoplasms 16Endometrial Neoplasms 16Esophageal Neoplasms 15Astrocytoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma, Bronchiolo-Alveolar 13

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 29Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7enfortumab vedotin 6Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × Bevacizumab × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT00268450 2018-07-12

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Medical University of South Carolina

Phase 2 Terminated
21 enrolled 4 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00506155 2016-03-31

Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
60 enrolled 10 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00234494 2016-03-14

Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

Hoosier Cancer Research Network

Phase 2 Completed
45 enrolled 11 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡